InvestorsHub Logo
Followers 5
Posts 359
Boards Moderated 0
Alias Born 01/10/2019

Re: None

Monday, 07/22/2019 1:01:33 PM

Monday, July 22, 2019 1:01:33 PM

Post# of 232961
Preliminary results from a Phase 1b proof-of-concept study assessing a single subcutaneous injection of Gilead Sciences' (GILD -0.2%) HIV capsid function inhibitor GS-6207 in HIV-positive patients showed significant reductions in HIV-1 RNA compared to placebo. The data were presented at the International AIDS Society Conference on HIV Science in Mexico City.
No serious adverse events or discontinuations were reported.
GS-6207 has Breakthrough Therapy status for multidrug-resistant HIV.
Development is ongoing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News